Review ArticleReviews and Contemporary Updates
Endocrine Therapy for Early Breast Cancer: Updated Review
Alexander Tremont, Jonathan Lu and John T. Cole
Ochsner Journal December 2017, 17 (4) 405-411;
Alexander Tremont
1Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA
DOJonathan Lu
2Department of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA
MBBSJohn T. Cole
2Department of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA
3The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA
MDREFERENCES
- 1.↵
- Siegel RL,
- Miller KD,
- Jemal A
- 2.↵
- Kohler BA,
- Sherman RL,
- Howlader N,
- et al.
- 3.↵
- Bland KI,
- Copeland EM
- 4.↵
- 5.↵
- Boyd S
- 6.↵
- 7.↵
- Harper MJ,
- Walpole AL
- 8.↵
- 9.↵
- Robert NJ
- 10.↵Consensus conference. Adjuvant chemotherapy for breast cancer. JAMA. 1985 12 27; 254 24: 3461- 3463. pmid:4068189
- 11.↵‘Nolvadex' Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer. 1988 6; 57 6: 608- 611. pmid:2900647
- 12.↵
- Band PR
- 13.↵
- Mamounas EP
- 14.↵
- Fisher B,
- Costantino J,
- Redmond C,
- et al.
- 15.↵
- Fisher B,
- Dignam J,
- Bryant J,
- et al.
- 16.↵Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 5 14-20; 365 9472: 1687- 1717. pmid:15894097
- 17.↵
- Davies C,
- Godwin J,
- Gray R,
- et al.
- 18.↵
- Buzdar AU,
- Jonat W,
- Howell A,
- et al.
- 19.↵
- Howell A,
- Cuzick J,
- Baum M,
- et al.
- 20.↵
- Cuzick J,
- Sestak I,
- Baum M,
- et al.
- 21.↵
- Thürlimann B,
- Keshaviah A,
- Coates AS,
- et al.
- 22.↵
- Perez EA,
- Josse RG,
- Pritchard KI,
- et al.
- 23.↵
- Coates AS,
- Keshaviah A,
- Thürlimann B,
- et al.
- 24.↵
- Smith I,
- Yardley D,
- Burris H,
- et al.
- 25.↵Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015 10 3; 386 10001: 1341- 1352. doi: 10.1016/S0140-6736(15)61074-1. pmid:26211827
- 26.↵
- Jakesz R,
- Jonat W,
- Gnant M,
- et al.
- 27.↵
- Coombes RC,
- Hall E,
- Gibson LJ,
- et al.
- 28.↵
- Davies C,
- Pan H,
- Godwin J,
- et al.
- 29.↵
- Gray RG,
- Rea D,
- Handley K,
- et al.
- 30.↵
- Goss PE,
- Ingle JN,
- Pritchard KI,
- et al.
- 31.↵
- Mamounas EP,
- Bandos H,
- Lembersky BC,
- et al.
- 32.↵
- Blok EJ,
- van de Velde CJH,
- Meershoek-Klein Kranenbarg EM,
- et al.
- 33.↵
- Tjan-Heijnen VC,
- Van Hellemond IE,
- Peer PG,
- et al.
- 34.↵
- Zhang Y,
- Schnabel CA,
- Schroeder BE,
- et al.
- 35.↵
- Jankowitz RC,
- Cooper K,
- Erlander MG,
- et al.
- 36.↵
- Rutqvist LE,
- Johansson H;
- 37.↵
- Sgroi DC,
- Sestak I,
- Cuzick J,
- et al.
- 38.↵
- Sestak I,
- Zhang Y,
- Schroeder B,
- et al.
- 39.↵
- Zhang Y,
- Jerevall P,
- Schroeder B,
- et al.
- 40.↵
- Sgroi DC,
- Carney E,
- Zarrella E,
- et al.
- 41.↵
- Sanft T,
- Aktas B,
- Schroeder B,
- et al.
In this issue
Endocrine Therapy for Early Breast Cancer: Updated Review
Alexander Tremont, Jonathan Lu, John T. Cole
Ochsner Journal Dec 2017, 17 (4) 405-411;